Aditya Birla Capital Q1: consolidated PAT +40% YoY to ₹1,175 Cr, margins widen
PAT +38.1% YoY · revenue +28.2% · margins expanding · beat vs street
₹12,179.54 Cr
+28.2% YoY
₹1,174.7 Cr
+38.1% YoY
9.64%
+0.7pp YoY
₹4.46
Aditya Birla Capital delivered a broad-based, clean Q1 FY27. Consolidated profit after tax attributable to owners rose ~40% year-on-year to ₹1,174.7 Cr (company basis; +38% versus our year-ago ₹850.8 Cr) on statutory revenue from operations of ₹12,179.5 Cr, up 28% YoY. There were no exceptional items on either side of the comparison, so the growth is fully underlying. Sequentially, statutory revenue fell 9.5% and PAT was roughly flat on our records — a seasonality artifact rather than weakness: Q4 carries the annual peak in life-insurance policyholders' premium income (₹7,563 Cr in Q4 vs ₹5,704 Cr this quarter), and profitability held despite that mix shift. The company's own headline revenue of ₹14,731 Cr (+29%) is a wider segment measure that equity-accounts AMC, health and wellness.
Q1 FY-2027 vs prior quarters
The margin bridge is favourable: consolidated net profit margin expanded to 9.64% from 8.80% a year ago, powered by lending scale and improving insurance economics. The total lending book (NBFC + HFC) grew 32% YoY to ₹2,19,289 Cr, with housing-finance AUM up 50% to cross ₹50,000 Cr and HFC PBT up 95% YoY. Crucially, growth came with better asset quality — NBFC gross stage-3 improved to 1.30% and HFC to 0.41%, and RoA rose at both (NBFC 2.39%, HFC 2.12%). In protection, life-insurance individual first-year premium grew 20% to ₹952 Cr with net VNB margin up 756 bps to 15.1%, and health GWP jumped 50% to ₹2,196 Cr with market share up 200 bps to 16.2%; MF quarterly average AUM rose 6% to ₹4,27,675 Cr, taking group AUM +36% YoY to ₹7,52,745 Cr.
The stock went into the print at ₹407, up 3.6% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; PAT has now risen for 4 consecutive quarters.
Against our pre-result preview, which set a bar of 'steady growth,' the print clears it comfortably: group AUM of ₹7.53 lakh Cr runs ahead of the ₹6.0–6.2 lakh Cr we flagged, and basic EPS of ₹4.46 beats the ~3.52 consensus in that read (no fresh independent Q1 FY27 consensus surfaced in search). Management gives no formal earnings guidance, so there is no outlook to grade the beat against. The watch item we flagged on capital did materialise — the ₹4,000 Cr preferential raise (₹2,880 Cr from promoter Grasim, ₹920 Cr from IFC, ₹200 Cr from Suryaja) closed in the quarter, of which ₹2,993 Cr is already deployed (87.5% earmarked for NBFC growth); the raise lifts paid-up equity to ₹2,734.2 Cr and is the reason EPS growth (+38%) modestly trails PAT growth. Alongside results the board granted ESOPs/PSUs and appointed a new CTO (effective 3 Aug) — governance items, not earnings drivers.
W1
Asset quality as the book scales: NBFC gross stage-3 at 1.30% and HFC at 0.41% — watch for delinquency creep against +32% YoY lending growth
W2
Deployment and RoE of the ₹4,000 Cr raise (₹2,993 Cr utilised, 87.5% for NBFC growth) — track whether returns keep pace with the enlarged equity base
W3
Insurance profitability durability: life VNB margin 15.1% (+756 bps YoY) and health combined ratio 106% (from 107%) — path to sub-100%
Clean print, no exceptional items this quarter (both standalone & consolidated). Consolidated PAT ₹1,174.70 Cr is attributable to owners; ₹1,223.85 Cr including non-controlling interests (NCI ₹49.15 Cr). Company reports +40% YoY on its Ind AS 117-restated year-ago base (₹838.6 Cr, this filing's own comparative); our records' year-ago base ₹850.8 Cr gives +38%. Q4 comparative also restated (filing shows ₹1,011 Cr vs our records' ₹1,164.7 Cr). Press-release headline revenue ₹14,731 Cr is consolidated SEGMENT revenue (AMC/health/wellness equity-accounted, not consolidated); statutory revenue from operations is ₹12,179.54 Cr. Unaudited, limited review.
Informational and educational content only. Not investment advice.